vitamin-d-2 has been researched along with Urinary-Tract-Infections* in 2 studies
1 trial(s) available for vitamin-d-2 and Urinary-Tract-Infections
| Article | Year |
|---|---|
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.
The objective of this study was to determine the maximum tolerated dose and safety of LR-103, a Vitamin D analogue, in patients with advanced cancer.. In Step A, patients received oral LR-103 once daily in 14-day cycles with intra-patient dose escalation per accelerated dose escalation design. Dose limiting toxicity for Step A was defined as ≥grade 2 hypercalcemia and/or >grade 2 other toxicities. Starting dose was 5 µg/day. Step B used a 3+3 design starting at Step A maximum tolerated dose with 28-day cycles. Dose limiting toxicity was defined as ≥grade 3 hypercalcemia or any grade 3 or 4 non-hematologic toxicity, except hypercalciuria.. Twenty-one patients were enrolled; eight were treated in Step A. At dose level 3 (15 µg/day), two patients had dose limiting toxicity. One had grade 4 hyperuricemia. The other had grade 4 GGT plus grade 3 alkaline phosphatase, fatigue and urinary tract infection (UTI). Dose level 2 (10 µg/day) was the maximum tolerated dose for Step A and was starting dose for Step B. The dose was escalated to dose level 5 (30 µg/day) with a patient experiencing grade 3 dose limiting toxicity of hypercalcemia. The study was discontinued before reaching the maximum tolerated dose due to sponsor decision. Modest increases in serum osteocalcin and calcium and decrease in parathyroid hormone were noted. Best response was stable disease; four patients were on therapy for six months or longer.. Step A dose limiting toxicities limited accelerated dose escalation. The maximum tolerated dose of LR-103 was not reached prior to study termination and this agent is no longer being developed. Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Calcium; Dose-Response Relationship, Drug; Ergocalciferols; Female; Humans; Hypercalcemia; Hypercalciuria; Male; Maximum Tolerated Dose; Middle Aged; Muscle Fatigue; Neoplasms; Osteocalcin; Parathyroid Hormone; Urinary Tract Infections | 2015 |
1 other study(ies) available for vitamin-d-2 and Urinary-Tract-Infections
| Article | Year |
|---|---|
Bladder rupture following osteoporotic pubic ramus and sacral insufficiency fractures.
We present a case report of an 86-year-old lady with pubic ramus and sacral insufficiency fractures who developed extra-vesical bladder rupture following displacement of the pubic ramus fracture, a very unusual complication. Topics: Accidental Falls; Aged, 80 and over; Ergocalciferols; Fecal Incontinence; Female; Fractures, Stress; Humans; Organometallic Compounds; Osteoporosis, Postmenopausal; Pubic Bone; Radiography; Rupture; Sacrum; Thiophenes; Urinary Bladder; Urinary Tract Infections; Vitamin D | 2010 |